AngioDynamics (AngioDynamics) Total Stockholders Equity

: $218.7 Mil (As of Feb. 2024)

View and export this data going back to 2004. Start your Free Trial

AngioDynamics's Total Stockholders Equity for the quarter that ended in Feb. 2024 was $218.7 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. AngioDynamics's Book Value per Share for the quarter that ended in Feb. 2024 was $5.41. The ratio of a company's debt over equity can be used to measure how leveraged this company is. AngioDynamics's Debt-to-Equity for the quarter that ended in Feb. 2024 was 0.00.

AngioDynamics Total Stockholders Equity Historical Data

The historical data trend for AngioDynamics's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AngioDynamics Annual Data

Trend

May14

May15

May16

May17

May18

May19

May20

May21

May22

May23

Total Stockholders Equity

Get a 7-Day Free Trial

614.82

454.87

439.46

424.49

378.30

AngioDynamics Quarterly Data
	May19	Aug19	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23	Nov23	Feb24
Total Stockholders Equity	Get a 7-Day Free Trial															397.66	378.30	427.80	401.23	218.70

AngioDynamics (NAS:ANGO) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

AngioDynamics's Book Value per Share for the quarter that ended in Feb. 2024 is

Book Value per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(218.698	-	0)	/	40.4245
	=	5.41

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

AngioDynamics's Debt-to-Equity for the quarter that ended in Feb. 2024 is

Debt-to-Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	0)	/	218.698
	=	0.00

AngioDynamics Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of AngioDynamics's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

AngioDynamics (AngioDynamics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » AngioDynamics Inc (NAS:ANGO) » Definitions » Total Stockholders Equity

Comparable Companies

Traded in Other Exchanges

UG2:Germany

Address

14 Plaza Drive, Latham, NY, USA, 12110

Website

https://www.angiodynamics.com

AngioDynamics Inc designs manufactures, and sells medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and for use in oncology and surgical settings. It generates maximum revenue from Endovascular Therapies. Geographically, the company derives a majority of its revenue from the United States.

Executives

Lorinda Burgess	director	22 WEST FRONTAG ROAD, NORTHBROOK IL 60093
Karen A Licitra	director	C/O SI-BONE, INC., 471 EL CAMINO REAL, SUITE 101, SANTA CLARA CA 95050
Michael E Tarnoff	director	C/O ANGIODYNAMICS, INC., 14 PLAZA DRIVE, LATHAM NY 12110
Scott Centea	officer: SVP/GM, VIT	C/O ANGIODYNAMICS, INC., 14 PLAZA DRIVE, LATHAM NY 12110
Dave Helsel	officer: SVP Global Operations and R&D	400 WOOD ROAD, BRAINTREE MA 02184
Laura Piccinini	officer: SVP International	C/O ANGIODYNAMICS INC., 14 PLAZA DRIVE, LATHAM NY 12110
Stephen A Trowbridge	officer: SVP and General Counsel	14 PLAZA DRIVE, LATHAM NY 120110
James C Clemmer	director, officer: President and CEO	COVIDIEN PLC, 15 HAMPSHIRE STREET, MANSFIELD MA 02048
Wesley Johnson	director
Chad Thomas Campbell	officer: SVP/GM, Vascular Access	140 POKANOKET PATH, WRENTHAM MA 02093
Warren Jr Nighan	officer: SVP Quality and Regulatory	ANGIODYNAMICS, INC., 14 PLAZA DRIVE, LATHAM NY 12110
Richard C Rosenzweig	officer: SVP and General Counsel	C/O DENTSPLY SIRONA INC., 13320 BALLANTYNE CORPORATE PLACE, CHARLOTTE NC 28277
Kevin J Gould	director	247 WASHINGTON STREET, DUXBURY MA 02332
Brent J. Boucher	officer: SVP and GM of Oncology	14 PLAZA DRIVE, LATHAM NY 12110
Michael Greiner	officer: EVP and CFO	C/O VISTAPRINT, 95 HAYDEN AVENUE, LEXINGTON MA 02421